A systematic review and meta-analysis of 40 randomized clinical trials involving 11,576 patients reveals that locoregional therapies (LRTs) for hepatocellular carcinoma (HCC) differ significantly in efficacy. Researchers found that surgery with adjuvant therapy provides superior progression-free survival (PFS) and overall survival (OS) compared to surgery alone, radiofrequency ablation (RFA), or various embolization techniques. The analysis indicates a hierarchy in treatment effectiveness, with surgery-based interventions leading to better patient outcomes than embolization-based options.
Meta-Analysis by Patel KR, Menon H (…) Escorcia FE et 3 al. in JAMA Netw Open